Seek Labs
Seek Labs is a biotechnology company headquartered in Salt Lake City, Utah, dedicated to advancing scientific discovery and delivering universal healthcare solutions. The company specializes in next-generation point-of-care molecular diagnostics and programmable CRISPR-based therapeutics, aiming to bridge the gap between disease outbreak and intervention. Powered by its proprietary AI discovery engine, BioSeeker™, Seek Labs is building a modular, full-stack system that enables rapid response to emerging pathogens, scalable precision treatments, and accessible diagnostics. The company is committed to global health innovation, sustainability, and community engagement, and is a proud member of Utah's BioHive life sciences ecosystem. Seek Labs' mission is to empower individuals with healthcare solutions tailored to their specific needs, revolutionizing the detection and treatment of diseases for both human and animal health.
Patents
What We Do
An AI-powered discovery engine that identifies pathogen-specific vulnerabilities, enabling rapid design of diagnostics and CRISPR-based therapeutics. It underpins Seek Labs’ innovation platforms and the Global Disease Atlas, and has recently mapped high-burden mosquito-borne and veterinary diseases.
A programmable CRISPR-based therapeutic platform designed to target and ablate pathogen genomes, enabling fast, precise, and scalable interventions for diseases such as RSV, measles, African Swine Fever, Chikungunya, West Nile Virus, and Zika.
A portable, instrument-free molecular diagnostic device that delivers rapid, lab-grade results at the point of care, validated for pathogens like White Spot Syndrome Virus (WSSV) in shrimp and showcased for aquaculture disease detection.
A field diagnostic kit for rapid detection of White Spot Syndrome Virus in shrimp, validated in collaboration with Florida Atlantic University and ShrimpVet, providing accurate results at 24 hours post-infection without lab infrastructure.
A real-time, AI-powered genomic map of the world’s most dangerous pathogens, guiding the development of pan-pathogen, programmable therapeutics and diagnostics. Now expanded to include veterinary diseases such as ASFV, Capripox, and CSFV.
CRISPR-based systems targeting African Swine Fever Virus, shown to prolong survival and reduce viral load in infected pigs during in vivo trials.
BioSeeker™ is an AI discovery engine that identifies high-impact genetic targets, powering the design of rapid diagnostics and programmable therapeutics. It serves as the intelligence layer for Seek Labs’ platforms, enabling faster timelines and smarter decisions at global scale.
PTAP™ Therapeutics is a platform for developing precision medicines that irreversibly disable disease at the genomic level. These therapeutics target and ablate exact pathogen sequences, delivering fast, adaptable interventions for urgent health threats.
SeekIt™ is a fully self-contained diagnostic platform that delivers lab-grade molecular testing directly to patients without the need for instruments, power, or infrastructure. It provides fast, accurate results in diverse settings, from clinics to outbreak zones.
An adaptive genomic map built by BioSeeker™ that reveals vulnerable points in evolving diseases, guiding the rapid development of programmable therapeutics and diagnostics to outpace disease spread. Now includes both human and veterinary pathogens.
A paid, temporary mid-level position for experienced professionals reentering the workforce after a career break, offering specialized training, mentorship, and support.
Application Area
Biologics
Vaccines
Digital Health Technologies
Show More (1)Drugs
Key People
Chief Executive Officer (CEO)
Vice President of Pharmaceutical Research
Vice President of Research
Vice President of Veterinary Pharmaceutical Development
Chief Strategy Officer
Co-Founder, Advisor (Former Chief Business Development Officer)
News & Updates
Seek Labs was named an Emerging finalist in the Healthcare and Life Sciences category for the 2024 Utah Business Innovation Awards, recognizing the innovation of SeekIt™ diagnostics.
Dr. Alison O’Mahony, VP of Pharmaceutical Research, was honored for her leadership and commitment to innovative CRISPR-based therapeutics.
Dr. Anindita Roy, VP of Research, received the 2025 Women Tech Council Rising Star Award for her contributions to diagnostics innovation.
Seek Labs was chosen to participate in the ARPA-H Investor Catalyst Hub Spoke Network and RRPV, supporting rapid response to health threats.
CEO Jared Bauer discusses the personal motivation behind Seek Labs and the development of BioSeeker, PTAP, and SeekIt as a modular system to accelerate disease response.
An exploration of the resurgence of measles, the limitations of relying solely on vaccines, and how BioSeeker and PTAP enable proactive global preparedness.